Objectives: Capnocytophaga spp. are often reported to cause bacteraemia and extra-oral infections and are characterized by their significant contribution to resistance to b-lactam and macrolide-lincosamidestreptogramin antibiotics in the human oral microbiota. The implication of mutations in the quinolone resistance-determining region (QRDR) of DNA gyrase A and B (gyrA and gyrB) and topoisomerase IV (parC and parE) of fluoroquinolone (FQ)-resistant Capnocytophaga spp., hitherto unknown, was explored in this study.
Introduction
Capnocytophaga spp. are fastidious capnophilic/anaerobic (able to grow in an atmosphere containing 5%-10% carbon dioxide) Gram-negative gliding bacilli isolated from the human oropharyngeal flora.
1,2 Capnocytophaga spp. are 'difficult-to-cultivate' bacteria whose carriage in adults and children has recently been estimated at 100%. 1, 3 Human oral species are often reported to cause bacteraemia and various extra-oral infections in both immunocompromised and immunocompetent hosts. [4] [5] [6] The genus Capnocytophaga is characterized by its high contribution to b-lactam resistance (from 16% in healthy patients to 82% in periodontitis patients of CfxA2, CfxA3 or CSP-1 b-lactamase-producing isolates) and macrolide-lincosamide-streptogramin resistance [29% of Erm(F) or Erm(C) methylase-producing isolates] in the human oral microbiota. 3, 7, 8 Fluoroquinolones (FQs) have been widely used to treat nosocomial Gram-negative bacterial infections over the past two decades. The clonal spread of strains with FQ resistance mutations has become a serious problem. To our knowledge, FQ resistance has only been reported in 11 cases of general infection due to Capnocytophaga spp. 4, 6, 9, 10 FQ resistance could be more frequent, as shown by the study by Martino et al. 4 (56% of tested Capnocytophaga isolates). Its presence, especially in respiratory infections, is probably underestimated. 6 Quinolones target DNA gyrase and topoisomerase IV. DNA gyrase consists of two subunits encoded by gyrA and gyrB, while topoisomerase IV consists of two subunits encoded by parC and parE, which are homologous to gyrA and gyrB of DNA gyrase, respectively. 11 Alterations through mutations in the quinolone resistance-determining regions (QRDRs) of chromosomal DNA gyrase and topoisomerase IV genes confer FQ resistance. 12 The aim of this study was: (i) to determine the role of DNA gyrase and topoisomerase IV mutations (gyrA/gyrB and parC/parE, respectively) in resistant clinical Capnocytophaga isolates and in laboratory mutants selected in vitro on levofloxacinsupplemented medium; and (ii) to study the mutation frequencies of the strains.
Materials and methods
Two reference strains (S1/Capnocytophaga gingivalis ATCC 33624 and S5/Capnocytophaga sputigena ATCC 33612) and four Capnocytophaga spp. isolated from clinical samples were studied. Clinical Capnocytophaga spp. were isolated from the subgingival flora of patients with haematological cancer (C. gingivalis Aa6, C. gingivalis Ag44 and C. sputigena Ah47) 3 and from a lung infection (C. gingivalis A0). 6 Species-level identification was performed by analysis of 16S rRNA sequences. MICs were determined by the Etest method (bioMérieux, Craponne, France) for ofloxacin, norfloxacin, ciprofloxacin, levofloxacin and moxifloxacin 3 without standard interpretation available for the genus Capnocytophaga.
To evaluate mutation frequency, the reference strains S1/C. gingivalis ATCC 33624 and S5/C. sputigena ATCC 33612 were used as parental strains to select in vitro quinolone-resistant mutants (S1M1-4; S5M1-2) in two successive steps, by plating an inoculum of 10 10 bacteria onto blood agar medium (Columbia ! 5% sterile sheep blood, Bio-Rad Laboratories, Marnes-la-Coquette, France) and containing levofloxacin at either two or four times the MIC. After anaerobic incubation at 37 C for 48 h, colonies were counted and mutation frequencies were determined, relative to the total viable count of bacteria plated.
Laboratory mutants (S1MD, S5MD and Ag44MD; MD for mutant disc) derived from reference strains and from a clinical isolate (S1/C. gingivalis ATCC 33624, S5/C. sputigena ATCC 33612 and Ag44/C. gingivalis) were also obtained by successive inoculations, onto blood agar, of colonies taken from the vicinity of a disc containing 5 lg of levofloxacin (Bio-Rad Laboratories).
Pairs of PCR primers were designed to amplify the presumed QRDR of DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) of Capnocytophaga spp. (Table 1 ). Presumed QRDRs of Capnocytophaga spp. were positioned by sequence homology with Bacteroides fragilis or Escherichia coli [accession numbers from the National Center for Biotechnology Information (NCBI) database; Table 2 ]. DNA was amplified with an initial denaturation step at 94 C for 5 min, followed by 30 s at the annealing temperature (Table 1) , then a final extension step at 72 C for 7 min. Reference strains were used as positive controls and sterile water as negative control. To amplify parC, an extra pair of primers was necessary because of the low ParC sequence homology among the different species of Capnocytophaga, especially around the QRDR (up to only 73%). Amplifications were followed by subsequent sequencing. 3 Sequence analyses were performed using the NCBI BLAST program.
Results and discussion
The two reference strains and two of the four clinical isolates (Aa6 and Ag44) presented low FQ MIC values (ofloxacin, norfloxacin, ciprofloxacin, levofloxacin and moxifloxacin 0.012-0.5 mg/L; Table 2 ). The two other clinical isolates (Ah47 and A0) presented high MIC values of all FQs (ofloxacin, norfloxacin, ciprofloxacin and levofloxacin 32 to .256 mg/L), except for moxifloxacin (0.38-1.5 mg/L). The reference strain S1/C. gingivalis ATCC 33624 was plated onto agar containing levofloxacin at 0.5 and 1 mg/L (Table 2) . First-step mutants S1M1 and S1M2 were selected at a frequency of 10 #5 and 10
#8
, respectively. Second-step mutants S1M3 and S1M4, derived from S1M2 (plated onto agar containing levofloxacin at 1 and 2 mg/L), were selected at a mean frequency of 10 #3 and 10
#9
, respectively. Two in vitro mutants, C. gingivalis S1MD and Ag44MD, derived from the reference strain S1/C. gingivalis ATCC 33624 and clinical isolate Ag44/C. gingivalis, respectively, were obtained after four and five successive inoculations, respectively. A first-step mutant S5M1 derived from reference strain S5/C. sputigena ATCC 33612 was selected only on the plate at twice the MIC, at a Fluoroquinolone resistance of Capnocytophaga spp.
JAC frequency of 3%10

#9
. Bacterial growth was inhibited on the plate containing 1 mg/L levofloxacin. A second-step mutant S5M2, derived from S5M1, was obtained at a mean frequency of 5%10
. A mutant S5MD, derived from S5, was obtained after four successive inoculations. The duration and frequency of exposure to levofloxacin had an adverse impact on Capnocytophaga spp. resistance rates. Exposure to low antibiotic concentrations led to greater numbers of selected mutants. Both FQ-resistant isolates and in vitro mutants displayed higher MICs of second-generation FQs (ofloxacin, ciprofloxacin and norfloxacin) compared with third-generation FQs (levofloxacin and moxifloxacin) ( Table 2 ). These data therefore suggest that continued exposure to levofloxacin may lead to increased levels of FQ resistance in the genus Capnocytophaga.
In the genus Capnocytophaga, FQ exposure led to an increase in FQ MIC values. Then, in accordance with what was observed in B. fragilis, the MIC values evolved differently depending on the FQ agent. 13, 14 Bacterial tolerance to norfloxacin was the highest, followed by ciprofloxacin, ofloxacin, levofloxacin and finally moxifloxacin. Therefore, all FQs could be affected, attesting to crossresistance to FQs in Capnocytophaga spp. For the genus Capnocytophaga, because no data exist, FQ MIC data could be interpreted according to the interpretation standards for anaerobes issued by CA SFM (http://www.sfm-microbiologie.org/ UserFiles/files/casfm/CASFM2013vjuin.pdf), EUCAST (http://www. eucast.org/clinical_breakpoints/) or CLSI (http://clsi.org/). According to CA SFM 2013, MIC breakpoints were only available for 
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OFX, ofloxacin; CIP, ciprofloxacin; LVX, levofloxacin; MXF, moxifloxacin; NOR, norfloxacin. S5M1 mutants were selected from the parental strain S5 on levofloxacin at twice the MIC (0.5 mg/L). S5M2 mutants were selected from S5M1 mutants on levofloxacin at four times the MIC (2 mg/L). c S5MD, S1MD and Ag44MD were mutants selected from S5, S1 and Ag44, respectively, on blood agar with a 5 lg levofloxacin disc and able to grow in contact with the levofloxacin disc after successive inoculations (four, four and five, respectively). d S1M1 and S1M2 mutants were selected from the parental strain S1 on levofloxacin at two and four times the MIC (0.5 and 1 mg/L), respectively. S1M3 and S1M4 mutants were obtained from S1M2 mutants on levofloxacin at two and four times the MIC (1 and 2 mg/L), respectively. Table 2 ). The gyrA, gyrB, parC and parE QRDR nucleotide sequences of the clinical isolates and in vitro mutants were analysed and compared with those of reference strains S1/C. gingivalis ATCC 33624 and S5/C. sputigena ATCC 33612 ( Table 2 ). The locations of presumed QRDRs of Capnocytophaga spp. were positioned by sequence homology with B. fragilis or E. coli and are described in Table 2 . All resistant isolates and in vitro mutants of C. gingivalis carried a mutation in the QRDR of gyrA, leading to a substitution between amino acids 80 and 82 (G80N, D81G, S82F or S82Y) compared with WT reference strain S1/C. gingivalis ATCC 33624 and susceptible clinical isolates (Table 2) . Concerning the C. sputigena species, all resistant isolates and in vitro mutants carried a mutation in the QRDR of gyrA leading to a substitution between amino acids 80 and 86 compared with WT reference strain S5/C. sputigena ATCC 33612 and susceptible clinical isolates (D86Y for S5M1 and S5M2; G80D for S5MD). The systematic presence of gyrA mutations, in both FQ-resistant clinical isolates and in vitro mutants, was observed without mutational alteration of gyrB.
These gyrA mutants had different resistance phenotypes and these data suggested that, similar to what was observed in E. coli, but contrary to B. fragilis, the DNA gyrase of C. gingivalis could be a primary target for FQs, whereas topoisomerase IV would be the secondary target and would confer a high level of resistance. 13, 15, 16 According to Moon et al., 12 FQ-resistant E. coli isolates carried the same substitution in GyrA (S83L and D87N), but different types of substitutions in ParC. These various configurations were compared for their FQ MIC values: double substitutions in ParC at S80I and E84G were linked to significantly higher MICs than those for the isolates carrying other types of double mutations. The systematic substitution of position 80 of ParC was not found in Capnocytophaga spp. Maeda et al. 17 highlighted numerous spontaneous amino acid substitutions in the QRDRs of DNA topoisomerase IV with no alteration in ciprofloxacin susceptibility within viridans group streptococci. We showed that, in Capnocytophaga spp., the mutations observed in parC as in parE (Table 2) implied spontaneous amino acid substitutions of DNA topoisomerase IV subunits A and B with no alteration in FQ susceptibility.
The study highlighted the role of DNA gyrase A as the primary target of FQs in the genus Capnocytophaga. However, despite the difference between the FQ MICs of S5M1 and S5M2 (derived from S5/C. sputigena ATCC 33612), they carried only the same substitution D86Y in GyrA. This raises the possibility of other resistance mechanisms such as membrane impermeability, drug efflux, target protection and drug enzymatic modification. A plasmidmediated quinolone resistance determinant (such as the qnr gene), previously described in E. coli 18 and Aeromonas spp., 19 could also be involved, despite the fact that it has never been detected in anaerobes.
